Form 4: aTyr Pharma Director Sara Zaknoen Acquires Stock Options

Director Sara Zaknoen acquired 24,000 stock options in aTyr Pharma, Inc. on May 22, 2024.

Summary

• On May 22, 2024, Sara Zaknoen, a director of aTyr Pharma, Inc., acquired 24,000 stock options.
• The options have an exercise price of $1.86.
• The options vest fully on the earlier of May 22, 2025, or the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The options expire on May 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather a standard part of corporate governance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants to board members are a common practice in the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are typically structured to align the interests of the directors with those of the shareholders, encouraging long-term value creation.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates